undamentalytics Newsletter
Sign in

Akebia Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Akebia Therapeutics, Inc. had a net margin of -2.3%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin——<−999%−40.7%−69.1%−83.5%−130.6%−133.3%−32.2%−26.7%−43.3%−2.3%−13.5%
Return on equity−35.6%−51.7%−136.3%−77.3%−37.9%−54.4%−120.8%−177.2%————−103.0%
Return on assets−33.4%−47.8%−61.3%−22.2%−21.1%−31.6%−54.4%−48.1%−21.3%−17.4%−30.0%−1.8%−8.2%
R&D as % of revenue——>999%127.4%140.1%96.4%74.2%69.9%44.4%32.4%23.5%26.4%32.2%
SG&A as % of revenue——>999%14.9%41.9%44.6%52.3%82.3%47.4%51.5%66.5%45.5%51.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

5 of 7 checks passed · June 30, 2026
What it owns · $350m
Short-term assets $230mLonger-term assets $120m
What it owes, and who funded it · $350m
Short-term liabilities $161mLonger-term liabilities $164mShareholders' equity $25m
  • Short-term assets cover short-term liabilities $230m of assets due within a year against $161m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $230m short-term assets against $164m of longer-dated liabilities.
  • More cash than debt $156m of cash against $50m of debt.
  • Debt below 40% of shareholders' equity Debt is 198% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 198% over five years.
  • A year's operating cash flow covers at least 20% of debt $42m of operating cash flow against $50m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Akebia Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

23 /100

Weak moat

How hard Akebia Therapeutics's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -5.5% of total assets over 7 years.

  • Pricing power 12 / 20

    Gross margin has been a median 62.6%, moving by 23.5 percentage points (standard deviation) across 7 years.

  • Durability 10 / 20

    Operating margin has been a median -44.7%; its worst year was -130.1%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 9 years, at a median -37.0% of revenue.

  • Discipline 5 / 20

    The diluted share count rose 74.4% over five years; stock-based pay has been a median 6.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (28 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AKBA vs PBYIAKBA vs IDYAAKBA vs ANABAKBA vs VALN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Akebia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Akebia Therapeutics, Inc.